Labetuzumab govitecan
Product Specifications
UNSPSC Description
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3].
Target Antigen
Antibody-Drug Conjugates (ADCs)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/labetuzumab-govitecan.html
Purity
98.66
Solubility
10 mM in DMSO
Smiles
[Labetuzumab govitecan]
Molecular Weight
154000 (average)
References & Citations
[1]Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. |[2]Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47. |[3]Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99681/Labetuzumab-govitecan-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99681/Labetuzumab-govitecan-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1469876-18-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items